Cogent Biosciences (COGT) Gets a Buy from LifeSci Capital
LifeSci Capital's Sam Slutsky maintains a Buy rating on Cogent Biosciences with a $53 price target. Slutsky, a 5-star analyst, has a 29.9% average return and a 48.46% success rate. H.C. Wainwright's Robert Burns also issued a Buy rating, while Robert W. Baird maintained a Hold rating. Slutsky covers the Healthcare sector, including stocks like Palvella Therapeutics and Celldex.
In a report released today, Sam Slutsky from LifeSci Capital maintained a Buy rating on Cogent Biosciences, with a price target of $53.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
According to TipRanks, Slutsky is a 5-star analyst with an average return of 29.9% and a 48.46% success rate. Slutsky covers the Healthcare sector, focusing on stocks such as Palvella Therapeutics, Cogent Biosciences, and Celldex.
In addition to LifeSci Capital, Cogent Biosciences also received a Buy from H.C. Wainwright’s Robert Burns in a report issued on November 13. However, on November 11, Robert W. Baird maintained a Hold rating on Cogent Biosciences (NASDAQ: COGT).
